AMP Capital Investors Ltd Has $24.10 Million Position in Becton Dickinson and Co (BDX)

AMP Capital Investors Ltd reduced its position in shares of Becton Dickinson and Co (NYSE:BDX) by 1.9% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 112,557 shares of the medical instruments supplier’s stock after selling 2,129 shares during the period. AMP Capital Investors Ltd’s holdings in Becton Dickinson and were worth $24,095,000 at the end of the most recent reporting period.

Several other hedge funds have also recently bought and sold shares of the stock. Legacy Advisors LLC grew its stake in shares of Becton Dickinson and by 7,000.0% in the fourth quarter. Legacy Advisors LLC now owns 497 shares of the medical instruments supplier’s stock worth $106,000 after purchasing an additional 490 shares in the last quarter. Amica Retiree Medical Trust grew its stake in shares of Becton Dickinson and by 325.0% in the fourth quarter. Amica Retiree Medical Trust now owns 510 shares of the medical instruments supplier’s stock worth $109,000 after purchasing an additional 390 shares in the last quarter. Almanack Investment Partners LLC. bought a new position in shares of Becton Dickinson and in the fourth quarter worth $109,000. FTB Advisors Inc. grew its stake in shares of Becton Dickinson and by 114.2% in the fourth quarter. FTB Advisors Inc. now owns 544 shares of the medical instruments supplier’s stock worth $116,000 after purchasing an additional 290 shares in the last quarter. Finally, Advisors Preferred LLC bought a new position in shares of Becton Dickinson and in the fourth quarter worth $126,000. 83.40% of the stock is currently owned by institutional investors and hedge funds.

How to Become a New Pot Stock Millionaire

Shares of Becton Dickinson and stock traded down $3.40 during trading on Monday, reaching $213.30. 1,498,022 shares of the company were exchanged, compared to its average volume of 1,428,612. The company has a quick ratio of 0.93, a current ratio of 1.54 and a debt-to-equity ratio of 1.04. Becton Dickinson and Co has a twelve month low of $175.66 and a twelve month high of $248.39. The stock has a market cap of $57,694.75, a PE ratio of 22.50, a price-to-earnings-growth ratio of 1.57 and a beta of 1.15.

Becton Dickinson and (NYSE:BDX) last announced its quarterly earnings data on Tuesday, February 6th. The medical instruments supplier reported $2.48 EPS for the quarter, topping analysts’ consensus estimates of $2.41 by $0.07. Becton Dickinson and had a return on equity of 16.19% and a net margin of 2.71%. The business had revenue of $3.08 billion during the quarter, compared to analysts’ expectations of $3.05 billion. During the same period in the previous year, the firm earned $2.33 earnings per share. The firm’s quarterly revenue was up 5.4% compared to the same quarter last year. analysts expect that Becton Dickinson and Co will post 10.94 EPS for the current fiscal year.

The firm also recently announced a quarterly dividend, which was paid on Friday, March 30th. Shareholders of record on Friday, March 9th were paid a $0.75 dividend. The ex-dividend date of this dividend was Thursday, March 8th. This represents a $3.00 dividend on an annualized basis and a yield of 1.41%. Becton Dickinson and’s payout ratio is 31.65%.

A number of research firms recently weighed in on BDX. Argus increased their price target on Becton Dickinson and to $235.00 and gave the company a “buy” rating in a research report on Thursday, December 14th. They noted that the move was a valuation call. KeyCorp started coverage on Becton Dickinson and in a research report on Friday, January 5th. They issued an “overweight” rating and a $260.00 price target for the company. Bank of America reissued a “buy” rating and issued a $260.00 price objective on shares of Becton Dickinson and in a research note on Friday, January 19th. Deutsche Bank set a $260.00 price objective on Becton Dickinson and and gave the stock a “buy” rating in a report on Friday, December 29th. Finally, Evercore ISI started coverage on Becton Dickinson and in a research report on Wednesday, January 3rd. They set an “outperform” rating and a $245.00 target price for the company. Six investment analysts have rated the stock with a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus target price of $240.53.

In related news, VP John E. Gallagher sold 5,346 shares of the company’s stock in a transaction dated Tuesday, February 27th. The stock was sold at an average price of $226.08, for a total transaction of $1,208,623.68. Following the sale, the vice president now owns 9,391 shares in the company, valued at $2,123,117.28. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Thomas E. Polen, Jr. sold 1,877 shares of the company’s stock in a transaction that occurred on Tuesday, March 13th. The shares were sold at an average price of $227.00, for a total value of $426,079.00. Following the completion of the sale, the executive vice president now owns 15,387 shares in the company, valued at approximately $3,492,849. The disclosure for this sale can be found here. Over the last three months, insiders sold 281,108 shares of company stock valued at $61,321,396. Insiders own 1.00% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This article was reported by Enterprise Leader and is the property of of Enterprise Leader. If you are reading this article on another domain, it was copied illegally and republished in violation of United States and international trademark and copyright law. The correct version of this article can be read at https://theenterpriseleader.com/2018/04/02/amp-capital-investors-ltd-sells-2129-shares-of-becton-dickinson-and-co-bdx.html.

Becton Dickinson and Profile

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Institutional Ownership by Quarter for Becton Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply